Treatment of standard risk medulloblastoma with craniospinal irradiation, carboplatin, and vincristine Journal Article


Authors: Bergman, I.; Jakacki, R. I.; Heller, G.; Finlay, J.
Article Title: Treatment of standard risk medulloblastoma with craniospinal irradiation, carboplatin, and vincristine
Abstract: Background. Improved outcome for children with medulloblastoma requires new treatment protocols which incorporate chemotherapeutic agents that are capable or eradicating minimal residual disease in the primary posterior fossa site and in the leptomeninges and whose toxicities are tolerable. Procedure. We treated 25 children with nondisseminated medulloblastoma with complete or near complete surgical resection of the posterior fossa tumor, 3,600 cGy craniospinal irradiation (CSRT) and 5,400 cGy posterior fossa irradiation followed by adjuvant chemotherapy with carboplatin and vincristine. Results. The estimated 3-year progression-free survival (PFS) was 0.73 (S.E. +/- 0.09) compared with a 3-year PFS of 0.69 in historical controls treated with surgical resection and CSRT bur without chemotherapy. Six relapses occurred outside the posterior fossa and one relapse occurred both in the posterior fossa and in the lateral ventricle. The major acute toxicities were myelosuppression, anorexia and neuropathy. Conclusions. Our experience with this adjuvant chemotherapy regimen with carboplatin and vincristine, as used by us, does not encourage its adoption in future clinical trials. (C) 1997 Wiley-Liss, Inc.
Keywords: cisplatin; chemotherapy; carboplatin; vincristine; medulloblastoma; childhood; children; phase-ii; radiation-therapy; brain-tumors; prospective randomized trial; society; cancer
Journal Title: Medical and Pediatric Oncology
Volume: 29
Issue: 6
ISSN: 0098-1532
Publisher: Wiley Liss  
Date Published: 1997-12-01
Start Page: 563
End Page: 567
Language: English
ACCESSION: WOS:A1997XY75800008
PROVIDER: wos
PUBMED: 9324345
DOI: 10.1002/(SICI)1096-911X(199712)29:6<563::AID-MPO8>3.0.CO;2-I
Notes: Article -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Glenn Heller
    399 Heller
  2. Jonathan Finlay
    67 Finlay